enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Walgreens launches specialty pharmacy unit to compete in new ...

   www.aol.com/finance/walgreens-launches-specialty...

   AllianceRx is the combined entity that Walgreens and its then-partner and PBM Prime Therapeutics formed in 2017 that will merge into the new business unit in August.

3. Express Scripts - Wikipedia

   en.wikipedia.org/wiki/Express_Scripts

   In 2018 the majority of the 5,000 St. Louis Express Scripts employees work in the complex. [48] Aerial view of 1 Express Way in St. Louis County, MO. George Paz, CEO of Express Scripts at the time of the move, was an UMSL graduate. [49]

4. Pharmacy benefit management - Wikipedia

   en.wikipedia.org/wiki/Pharmacy_benefit_management

   As of 2022, Caremark Rx, Express Scripts, OptumRx, Humana, Prime Therapeutics, and MedImpact Healthcare Systems were the six largest public PBMs that control 95% of the market, while the top three controlled 80% of the market. [42] As of 2024, the top 3 controlled a market of almost $600 billion. [6]

5. Amgen - Wikipedia

   en.wikipedia.org/wiki/Amgen

   2021: In March, the company announced it would acquire Five Prime Therapeutics and its lead candidate, bemarituzumab, for $1.9 billion. [93] [94] [95] In the same month, Amgen acquired Rodeo Therapeutics for $720 million. [96] [97] The FDA approved Amgen's Lumakras in May for treatment of patients with KRAS-G12C-mutated non-small cell lung ...

6. US accuses CVS of filling, billing government for illegal ...

   www.aol.com/news/us-accuses-cvs-filling-billing...

   (Reuters) -The U.S. Department of Justice announced a lawsuit on Wednesday accusing pharmacy chain CVS of filling illegal opioid prescriptions and billing federal health insurance programs ...

7. Cartesian Therapeutics Announces Positive Updated Results ...

   lite.aol.com/tech/story/0022/20241203/9312598.htm

   Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket ...